Market Research Life Sciences Market Research Pharmaceuticals Market Research Therapeutic Area Market Research Infectious Diseases Market Research

Infectious Disease Diagnostic Testing: World Market Analysis, 2024-2029

Best Price Guarantee Length Publisher Published Date SKU
from $6,300 281 Pages Kalorama Information November, 2024 KLI19331859
Best Price Guarantee
Price from $6,300
Length 281 Pages
Publisher Kalorama Information
Published Date November, 2024
SKU KLI19331859

Infectious Disease Diagnostic Testing: World Market Analysis, 2024-2029


Stay Ahead of the Curve with Infectious Disease Diagnostic Testing: World Market Analysis, 2024-2029: With the global demand for infectious disease IVD products projected to surge, understanding market trends is crucial for healthcare providers, investors, and industry stakeholders. This report offers a detailed analysis of the factors driving growth, including the increasing recognition of infectious diseases as a global health concern.

As infectious diseases continue to pose significant global health challenges, diagnostic testing has emerged as a vital tool in detecting and managing these threats. Today, infectious disease testing stands at the forefront of the rapidly expanding in vitro diagnostics (IVD) industry, representing one of its largest and most dynamic segments.
This comprehensive market research report from Kalorama Information delves into the world of infectious disease IVD, presenting unparalleled insights and forecasts for 2024-2029. Designed for industry professionals, investors, and market strategists, this report will equip you with the knowledge needed to stay ahead in a competitive and rapidly evolving sector.
Report Features:
  • Comprehensive Market Coverage: Understand the dynamic landscape of infectious disease diagnostics, spanning key test categories such as:
  • Healthcare-Associated Infections (HAIs)
  • COVID-19
  • Hepatitis
  • STIs
  • Influenza
  • HIV/AIDS
  • Tuberculosis
  • TORCH
  • Other infectious diseases (including Dengue Fever, Emerging Infections, Fungal, Lyme Disease, Malaria, Other Parasitic, RSV, Streptococcal)
  • Global Reach with Local Insights: Gain valuable perspectives on opportunities in diverse geographic regions, including North America, Western Europe, Asia/Pacific, and emerging markets across Central & South America, Africa, and the Middle East.
  • Strategic Market Drivers: Explore the macroeconomic and healthcare trends driving the need for advanced diagnostics and how aging populations and globalized threats are influencing market growth.
  • Competitive Intelligence: Analyze the leading players and their IVD innovations, helping you benchmark against industry leaders and identify potential partnerships or competitive advantages.
Scope and Methodology You Can Trust: Backed by Kalorama Information’s extensive experience and robust analytical frameworks, this report synthesizes data from public records, epidemiological research, key competitor analysis, and economic modeling. Our insights are further enriched by expert interviews and proprietary databases, ensuring you get actionable, reliable forecasts.


  • Executive Summary
    • A Mix of Traditional and Emerging Testing Technologies
    • Market Drivers
    • The World Infectious Disease Testing Market
      • Table World Infectious Disease Diagnostic Test Market, 2024-2029 ($ million)
      • Table World Infectious Disease Diagnostic Test Market, 2024-2029 ($ million)
    • Major Findings of the Report
      • Table Selected Infectious Diseases, Global Incidence, Prevalence, &Mortality, 2023 (COVID-19; Dengue Fever [symptomatic]; Hepatitis [all forms]; HIV/AIDS; HPV; Influenza [severe]; Sepsis; Sexually Transmitted Diseases [Chlamydia; Gonorrhea; Herpes HSV-2; Malaria; Syphilis; Trichomoniasis]; Tuberculosis; Typhoid Fever)
      • Table Selected Infectious Diseases: Global Incidence of New Cases, 2023 (million) (COVID-19; Dengue Fever [symptomatic]; Hepatitis [all forms]; HIV/AIDS; HPV; Influenza [severe]; Sepsis; Sexually Transmitted Diseases; Tuberculosis; Typhoid Fever)
      • Table Selected Sexually Transmitted Diseases: Global Incidence of New Cases and Chronic Cases, 2023 (million) (Sexually Transmitted Diseases [Chlamydia; Gonorrhea; Herpes HSV-2; HIV/AIDS; Malaria; Syphilis; Trichomoniasis])
      • Table Selected Infectious Diseases: Global Deaths, 2023 (thousands) (COVID-19; Dengue Fever [symptomatic]; Hepatitis [all forms]; HIV/AIDS; HPV; Influenza [severe]; Sepsis; Tuberculosis; Typhoid Fever)
    • Scope and Methodology
  • Market Environment
    • Overview
    • Population
      • Table Population by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
      • Table Global Population, by Region, 2023 vs. 2029 (million) (Asia/Pacific; North America; Western Europe; Other Regions)
    • Age Distribution
      • Table Population 50 Years & Older by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
      • Table Population 65 Years & Older by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
    • Macroeconomic Environment
      • Global Economic Outlook
        • Table Gross Domestic Product by Country, 2023-2029 ($ billion) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
        • Table Per Capita Gross Domestic Product by Country, 2023-2029 (dollars) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
    • Global Healthcare Trends
      • Infectious Disease Cases
        • Table Number of Infectious Disease Cases by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
        • Table Number of Global Infectious Disease Cases, by Region, 2023 vs. 2029 (million) (Asia/Pacific; North America; Western Europe; Other Regions)
      • Medical Providers
        • Table Medical Providers, Selected Countries, 2021 (Africa/M.E.; Canada; Central/South America; China; Eastern Europe; France; Germany; India; Italy; Japan; Mexico; Other Asia/Pacific; Other Western Europe; South Korea; Spain; United States)
      • Patient Activity
        • Table Hospital Admissions by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
        • Table Inpatient Days by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
        • Table Outpatient Consultations by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
        • Table IVD Tests by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
        • Table In Vitro Diagnostic (IVD) Tests, by Region, 2023 vs. 2029 (million) (Asia/Pacific; North America; Western Europe; Other Regions)
  • Infectious Disease IVD Products & Markets
    • Overview
      • Table Global Infectious Disease IVD Products Demand by Type, 2024-2029 ($ million) (COVID-19; Healthcare-Associated Infections [HAIs]; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
      • Table Global Infectious Disease IVD Products Demand by Disease/Area, 2024-2029 ($ million) (COVID-19; Healthcare-Associated Infections [HAIs]; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
    • Healthcare-Associated Infections (HAIs)
      • Table Global Healthcare-Associated Infection (HAIs) IVD Products Demand, 2024-2029 ($ million) (Pathogen/Disorder: C. diff, MRSA, Sepsis, VRE, Other HAIs; Site: Laboratory Tests, POC Tests; Technology: Immunoassay, Microbiology, Molecular)
      • Clostridium difficile (C. diff)
      • Sepsis
      • Methicillin-Resistant Staphylococcus Aureus (MRSA)
      • Vancomycin-Resistant Enterococcus (VRE)
      • Other HAIs
    • COVID-19
      • Table Global COVID-19 IVD Products Demand, 2024-2029 ($ million) (Site: Laboratory Tests, POC Tests; Technology: Immunoassay, Molecular Tests)
    • Hepatitis IVD Products
      • Table Global Hepatitis IVD Products Demand, 2024-2029 ($ million) (Pathogen/Disorder: Hepatitis B, Hepatitis C, Other; Site: Blood Screens, Laboratory Tests, POC Tests; Technology: Immunoassay, Molecular)
    • Sexually Transmitted Infections (STIs)
      • Table Global Sexually Transmitted Infection (STI) IVD Products Demand, 2024-2029 ($ million) (Pathogen/Disorder: Chlamydia, Gonorrhea, HPV, HSV-2 [Herpes Simplex], Syphilis, Other STIs; Site: Blood Screens, Laboratory Tests, POC Tests; Technology: Immunoassay, Microbiology, Molecular)
      • Human Papillomavirus (HPV)
      • Chlamydia Trachomatis (Chlamydia)
      • Gonorrhea
      • Herpes Simplex Virus 2 (HSV-2)
      • Syphilis
      • Other Sexually Transmitted Disease (STD) IVD Products
    • Influenza
      • Table Global Influenza IVD Products Demand, 2024-2029 ($ million) (Site: Laboratory Tests, POC Tests; Technology: Immunoassay, Microbiology, Molecular)
    • HIV/AIDS IVD Products
      • Table Global HIV/AIDS IVD Products Demand, 2024-2029 ($ million) (Site: Blood Screens, Laboratory Tests, POC Tests; Technology: Immunoassay, Molecular)
    • Tuberculosis (TB)
      • Table Global Tuberculosis IVD Products Demand, 2024-2029 ($ million) (Site: Laboratory Tests, POC Tests; Technology: Immunoassay, Microbiology, Molecular)
    • TORCH
      • Table Global TORCH IVD Products Demand, 2024-2029 ($ million)
    • All Other Infectious Disease IVD Products
      • Table Global Other Infectious Disease IVD Products Demand, 2024-2029 ($ million) (Dengue Fever; Emerging Infections; Fungal; Lyme Disease; Malaria; Other Parasitic; RSV; Streptococcal; All Other)
      • Malaria
      • Emerging Infections
      • Chikungunya
      • Fungal Infections
      • Other Parasitic Conditions
      • Lyme Disease
      • Respiratory Syncytial Virus (RSV)
      • Streptococcal Infections
      • Dengue Fever
      • All Other Products
    • Global Infectious Disease IVD Technologies
      • Table Global Infectious Disease IVD Products Demand by Technology, 2024-2029 ($ million) (Immunoassay, Microbiology, Molecular)
      • Immunoassays
        • Table Global Immunoassay Infectious Disease IVD Products Demand, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other)
      • Molecular Technologies
        • Table Global Molecular Infectious Disease IVD Products Demand, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; Tuberculosis; Other)
      • Microbiological Testing
        • Table Global Microbiology Infectious Disease IVD Products Demand, 2024-2029 ($ million) (HAIs/Sepsis; Influenza; STIs; Tuberculosis; Other)
      • Pathogen ID/AST Techniques
        • Table Global Microbiology ID/AST IVD Products Demand, 2024-2029 ($ million) (Blood Culture; Chromogenic Media; ID/AST Auto; ID/AST Panels; Mass Spectrometry; Rapid Microbiology)
      • Automated ID/AST Products
      • Manual Panels & Reagents
      • Producers
    • Global Infectious Disease IVD Demand by Market
      • Table Global Infectious Disease IVD Products Demand by Site, 2024-2029 ($ million) (Blood Screens; Laboratory; Point-of-Care)
      • Table Global Laboratory Infectious Disease IVD Products Demand, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
      • Table Global Point-of-Care Infectious Disease IVD Products Demand, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; Tuberculosis; Other Infections)
  • Global Markets
    • Overview
      • Table Infectious Disease IVD Products Demand, by Country, 2024-2029 ($ million) (Asia/Pacific [China, India, Japan, South Korea, Other APAC]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other Western Europe]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
    • North America
      • Table North America: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
      • United States
        • Table United States: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
      • Canada
        • Table Canada: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
      • Mexico
        • Table Mexico: Infectious Disease IVD Products Demand by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
    • Western Europe
      • Table Western Europe: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
      • Germany
        • Table Germany: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
      • France
        • Table France: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
      • United Kingdom
        • Table United Kingdom: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
      • Italy
        • Table Italy: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
      • Spain
        • Table Spain: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
      • Other Western Europe
        • Table Other Western Europe: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
    • Asia/Pacific
      • Table Asia/Pacific: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
      • China
        • Table China: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
      • Japan
        • Table Japan: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
      • India
        • Table India: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
      • South Korea
        • Table South Korea: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
      • Other Asia/Pacific
        • Table Other Asia/Pacific: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
    • Other Regions
      • Table Other Regions: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
      • Africa/Middle East
        • Table Africa/Middle East: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
      • Central & South America
        • Table Central & South America: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
      • Eastern Europe
        • Table Eastern Europe: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
  • Company Profiles
    • Abbott Laboratories
      • Infectious Diseases – Molecular
      • COVID-19
      • HIV Point of Care
      • Blood Bank
    • Becton Dickinson and Company
      • Molecular Microbiology
      • Traditional Microbiology - ID/AST
      • Blood Culture
      • Hospital Acquired Infections
      • Molecular Microbiology
      • Traditional Microbiology - ID/AST
      • Blood Culture
      • Mass Spectrometry
    • Bio-Rad Laboratories
      • Immunoassays
    • bioMérieux
      • Traditional Microbiology
      • Blood Culture
      • Immunoassays
      • BIOFIRE Diagnostics Business
      • Mass Spectrometry
    • Bruker Corporation
    • Danaher Corporation
      • Tuberculosis
      • Microbiology
      • POC Testing Developments
    • DiaSorin
      • Recent Deals and Announcements
    • Grifols S.A.
      • Blood Transfusion Business
    • Hologic
      • PANTHER Molecular System
      • HIV Testing
      • Sexually Transmitted Infections
      • Infectious Diseases
    • QIAGEN
      • Tuberculosis
      • Molecular Expansion
    • QuidelOrtho Corporation
      • Solana Business
      • Molecular – Savanna
      • COVID-19
    • Roche Holding
      • Immunoassays
      • COVID-19
      • Blood Screening
      • HPV
      • Other Recent Developments
    • Siemens Healthineers
    • Thermo Fisher Scientific
      • Microbiology
      • Molecular Test Business
      • COVID-19

$6,300
$9,450
$12,600

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings